Serum insulin-like growth factor I (IGF-I) levels predominantly reflect the hepatic effect of growth hormone (GH). Compared with serum GH levels, which reflect pulsatile GH secretion, serum IGF-I levels exhibit no major diurnal variation and thus provide a better estimate of integrated GH secretion in an individual patient. Measurement of serum IGF-I levels allows reliable identification of states of GH excess. In contrast, in a large proportion of adults with severe GH deficiency, serum IGF-I levels are within the normal range. Serum IGF-I levels increase markedly in response to GH administration and are often used as a surrogate variable for overall responsiveness to such treatment. Current data, however, suggest a poor relationship between changes in or levels of IGF-I and efficacy variables such as body composition, muscle function and well-being. The use of serum IGF-I as a guide during dose titration in the initial phase of treatment and during long-term monitoring of GH replacement therapy in adults, and its use as a safety marker or predictor of future morbidity and mortality are discussed here.

1.
de Boer H, Blok GJ, Popp-Snijders C, Stuurman L, Baxter RC, van der Veen E: Monitoring of growth hormone replacement therapy in adults, based on measurements of serum markers. J Clin Endocrinol Metab 1996;81:1371–1377.
2.
Møller J, Jørgensen JOL, Lauersen T, Frystyk J, Næraa RW, Ørskov H, Christiansen JS: Growth hormone dose regimens in adult GH deficiency: Effects on biochemical growth markers and metabolic parameters. Clin Endocrinol (Oxf) 1993;39:403–408.
[PubMed]
3.
Isgaard J, Carlsson L, Isaksson OGP, Jansson J-O: Pulsatile intravenous growth hormone (GH) infusion to hypophysectomized rats increases insulin-like growth factor I messenger ribonucleic acid in skeletal tissues more effectively than continuous GH infusion. Endocrinology 1988;123:2605–2610.
[PubMed]
4.
Hoffman DM, O’Sullivan AJ, Baxter RC, Ho KKY: Diagnosis of growth hormone deficiency in adults. Lancet 1994;343:1064–1068.
[PubMed]
5.
Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ: Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab 2002;87:477–485.
[PubMed]
6.
Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KK: Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am J Physiol Endocrinol Metab 2001;281:E1191–E1196.
7.
Svensson J, Johannsson G, Bengtsson B-Å: Insulin-like growth factor-I in growth hormone-deficient adults: Relationship to population-based normal values, body composition and insulin tolerance test. Clin Endocrinol 1997;46:579–586.
[PubMed]
8.
Attanasio AF, Lamberts SWJ, Matranga AMC, Birkett MA, Bates PC, Valk NK, Hilsted J, Bengtsson B-Å, Strasburger CJ, and the Adult Growth Hormone Deficiency Study Group: Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment. J Clin Endocrinol Metab 1997;82:82–88.
[PubMed]
9.
Lissett CA, Murray RD, Shalet SM: Timing of onset of growth hormone deficiency is a major influence on insulin-like growth factor I status in adult life. Clin Endocrinol (Oxf) 2002;57:35–40.
[PubMed]
10.
Hilding A, Hall K, Wivall-Helleryd IL, Saaf M, Melin AL, Thoren M: Serum levels of insulin-like growth factor I in 152 patients with growth hormone deficiency, aged 19–82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab 1999;84:2013–2019.
[PubMed]
11.
Murray RD, Howell SJ, Lissett CA, Shalet SM: Pre-treatment IGF-I level is the major determinant of GH dosage in adult GH deficiency. Clin Endocrinol (Oxf) 2000;52:537–542.
[PubMed]
12.
Johannsson G, Bjarnason R, Bramnert M, Carlsson LMS, Degerblad M, Manhem P, Rosén T, Thorén M, Bengtsson B-Å: The individual responsiveness to growth hormone (GH) treatment in GH-deficient adults is dependent on the level of GH binding protein, body mass index, age and gender. J Clin Endocrinol Metab 1996;81:1575–1581.
13.
Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB: Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993;76:1610–1616.
[PubMed]
14.
Shalet SM, Toogood A, Rahim A, Brennan BMD: The diagnosis of growth hormone deficiency in children and adults. Endocr Rev 1998;19:203–223.
15.
Valk NK, van der Lely AJ, de Herder WW, Lindemans J, Lamberts SWJ: The effects of human growth hormone (GH) administration in GH-deficient adults: A 20-day metabolic ward study. J Clin Endocrinol Metab 1994;79:1070–1076.
[PubMed]
16.
Janssen YJH, Frölich M, Roelfsema F: A low starting dose of Genotropin in growth hormone-deficient adults. J Clin Endocrinol Metab 1997;82:129–135.
[PubMed]
17.
Drake WM, Coyte D, Camacho-Hübner C, Jivanji NM, Kaltsas G, Wood DF, Trainer PJ, Grossman AB, Besser GM, Monson JP: Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. J Clin Endocrinol Metab 1998;83:3913–3919.
[PubMed]
18.
Mandel S, Moreland E, Nichols V, Hanna C, LaFranchi S: Changes in insulin-like growth factor-I (IGF-I), IGF-binding protein-3, growth hormone (GH)-binding protein, erythrocyte IGF-I receptors, and growth rate during GH treatment. J Clin Endocrinol Metab 1995;80:190–194.
[PubMed]
19.
Thorén M, Hilding A, Baxter RC, Degerblad M, Wivall-Helleryd IL, Hall K: Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency. J Clin Endocrinol Metab 1997;82:223–228.
20.
Johannsson G, Rosén T, Bengtsson B-Å: Individualized dose titration of growth hormone (GH) during GH replacement in hypopituitary adults. Clin Endocrinol (Oxf) 1997;47:571–581.
[PubMed]
21.
Holmes SJ, Shalet SM: Which adults develop side-effects of growth hormone replacement? Clin Endocrinol 1995;43:143–149.
[PubMed]
22.
Johannsson G, Rosén T, Lindstedt G, Bosaeus I, Bengtsson B-Å: Effects of 2 years of growth hormone treatment on body composition and cardiovascular risk factors in adults with growth hormone deficiency. Endocrinol Metab 1996;3(suppl A):3–12.
23.
Bengtsson B-Å, Abs R, Bennmarker H, Monson JP, Feldt-Rasmussen U, Hernberg-Ståhl E, Westberg B, Wilton P, Wüster C: The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults. KIMS Study Group and the KIMS International Board. J Clin Endocrinol Metab 1999;84:3929–3935.
[PubMed]
24.
Gotherstrom G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B, Johannsson G: A prospective study of 5 years of GH replacement therapy in GH-deficient adults: Sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001;86:4657–4665.
25.
Svensson J, Stibrant Sunnerhagen K, Johannsson G: Five years of growth hormone replacement therapy in adults: Age- and gender-related changes in isometric and isokinetic muscle strength. J Clin Endocrinol Metab 2003;88:2061–2069.
[PubMed]
26.
Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, Chernausek SD, Mejia W, Le Roith D: Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001;50:1110–1118.
[PubMed]
27.
Sjögren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, LeRoith D, Törnell J, Isaksson OG, Jansson JO, Ohlsson C: Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999;96:7088–7092.
[PubMed]
28.
Domené HM, Bengolea SV, Martinez AS, Ropelato MG, Pennisi P, Scaglia P, Heinrich JJ, Jasper HG: Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004;350:570–577.
[PubMed]
29.
Oscarsson J, Ottosson M, Vikman-Adolfsson K, Frick F, Enerbäck S, Lithell H, Edén S: GH but not IGF-I or insulin increases lipoprotein lipase activity in muscle tissues of hypophysectomised rats. J Endocrinol 1999;160:247–255.
[PubMed]
30.
Linden D, Sjoberg A, Asp L, Carlsson L, Oscarsson J: Direct effects of growth hormone on production and secretion of apolipoprotein B from rat hepatocytes. Am J Physiol Endocrinol Metab 2000;279:E1335–E1346.
31.
Tsukahara H, Gordienko DV, Tonshoff B, Gelato MC, Goligorsky MS: Direct demonstration of insulin-like growth factor-I-induced nitric oxide production by endothelial cells. Kidney Int 1994;45:598–604.
[PubMed]
32.
Thum T, Tsikas D, Frolich JC, Borlak J: Growth hormone induces eNOS expression and nitric oxide release in a cultured human endothelial cell line. FEBS Lett 2003;555:567–571.
[PubMed]
33.
Weissberger AJ, Ho KY, Lazarus L: Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991:72:374–381.
[PubMed]
34.
Flyvbjerg A: Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 2000;43:1205–1223.
[PubMed]
35.
Sjogren K, Wallenius K, Liu JL, Bohlooly YM, Pacini G, Svensson L, Tornell J, Isaksson OG, Ahren B, Jansson JO, Ohlsson C: Liver-derived IGF-I is of importance for normal carbohydrate and lipid metabolism. Diabetes 2001;50:1539–1545.
[PubMed]
36.
Jørgensen JOL, Møller N, Lauritzen T, Christiansen JS: Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: Effects of circulating insulin-like growth factor-I and metabolic indices. J Clin Endocrinol Metab 1990;70:1616–1623.
[PubMed]
37.
Johansson J-O, Oscarsson J, Bjarnason R, Bengtsson B-Å: Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis. Metabolism 1996;45:362–369.
[PubMed]
38.
Swearingen B, Barker FG 2nd, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM, Zervas NT: Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419–3426.
[PubMed]
39.
Holdaway IM, Rajasoorya CR, Gamble GD, Stewart AW: Long-term treatment outcome in acromegaly. Growth Horm IGF Res 2003;13:185–192.
[PubMed]
40.
Shaneyfelt T, Husein R, Bubley G, Mantzoros CS: Hormonal predictors of prostate cancer: A meta-analysis. J Clin Oncol 2000;18:847–853.
[PubMed]
41.
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393–1396.
[PubMed]
42.
Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620–625.
[PubMed]
43.
Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T: Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: A population-based case-control study. Circulation 2002;106:939–944.
[PubMed]
44.
Vaessen N, Heutink P, Janssen JA, Witteman JC, Testers L, Hofman A, Lamberts SW, Oostra BA, Pols HA, van Duijn CM: A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 2001;50:637–642.
[PubMed]
You do not currently have access to this content.